Please login to the form below

gout

This page shows the latest gout news and features for those working in and with pharma, biotech and healthcare.

Horizon raised its revenue expectations for Krystexxa (pegloticase injection), a gout therapy that is already on the market, by the same amount.

Novartis bolsters anti-inflammatory R&D with $1.6bn IFM Tre buy

Heading the pack is IFM-2427, an NLRP3 antagonist that has just started a phase 1 clinical trial in healthy volunteers and has potential in chronic inflammatory disorders, including gout, atherosclerosis
Roche enters NASH race with deal to buy Jecure

Feldstein – sits apart from rival therapies and could have applications beyond NASH in other inflammatory disorders gout including inflammatory bowel disease and cardiovascular diseases.
Sanofi’s rare blood disorder drug Cablivi set for European approval

In addition to the orphan drug approvals, the CHMP also gave positive opinions to Gruenenthal’s gout treatment Duzallo (lesinurad/allopurinol), a follow-up to the company’s Zurampic (lesinurad) product.
Daily Brief: EULAR kicks off, Brexit lurches closer and Autolus prepares for IPO

On today’s agenda expect new trial data from Novartis' Ilaris in gout, Lilly's Oluminant in systemic lupus and AbbVie's new JAK inhibitor upadacitinib.
Ironwood claims FDA OK for former AZ gout drug

The US FDA has approved Ironwood Pharma's combination gout therapy Duzallo, but with a warning that it can cause serious kidney failure. ... Gout is a painful form of inflammatory arthritis caused by elevated levels of uric acid (UA) in the blood, and

More from news
Approximately 9 fully matching, plus 39 partially matching documents found.

Grünenthal's relentless pursuit of relief

We are involved in projects that go beyond pain - backed by our licence agreement with AstraZeneca for Zurampic in gout, a condition that causes joint pain flares and is diagnosed both
Deal Watch January 2017

230. Cymabay. Kowa. Exclusive licence in the US. Arhalofenate for gout p3 ready.
Deal Watch October 2016

Gout 2016. Ironwood. Lesinurad US. $265m royalties. Rhinitis 2016. Janssen. Rhinocort outside US.
Deal Watch June 2016

Zurampic, a Selective Uric Acid Reabsorption Inhibitor (SURI), works selectively to complement xanthine oxidase inhibitors (XOIs) in the treatment of hyperuricaemia associated with uncontrolled gout, and was approved by the EMA ... licence. 270.
Deal Watch April 2016

Another deal worth pondering about is the $265m exclusive license by AstraZeneca (AZ) of the approved Zurampic (lesuranid) plus a fixed dose combination with allopurinol for treatment of gout. ... 450. AstraZeneca (UK). Ironwood (US). US license and

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

THE OTHER SIDE OF … GOUT

She also has gout, an inflammatory condition that affects one in 40 adults in the UK and is on the rise. ... Could these low goals for treatment, alongside the hard-to-shift perception of gout, mean that doctors are not motivated to change their behaviour

More from PMHub
Approximately 1 fully matching, plus 0 partially matching documents found.

Add my company

Inclusion drives innovation. Attigo, a social enterprise, helps pharma and the socially conscious business shape the future by engaging with...

7 important considerations for creating an inclusive clinical trial website: You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...
Route 66: can remote working put two-thirds of us back on the road to engaged employment?: Pre-pandemic, 66% of the world’s workforce weren’t engaged in their jobs – Chris Ross examines how the rush to remote working has impacted employee engagement...
Demonstrating the value of HCP self-serve portals: Develop the art of setting KPIs and metrics aligned to your specific objectives, target personas, key educational messages, content, website features and journeys....